Effects of yoga in adults with type 2 diabetes mellitus: A meta-analysis

Journal of Diabetes Investigation

Volumn 8, Issue 2, 2017, Pages 201-209

  Cui, Jie ^a,b   Yan, Jun Hong ^c   Yan, Li Ming ^c   Pan, Lei ^c   Le, Jia Jin ^a   Guo, Yong Zhong ^d  

^a DONGHUA UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c BINZHOU MEDICAL UNIVERSITY HOSPITAL   (China)

^d NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Meta analysis; Type 2 diabetes; Yoga

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; CALCULATION; CHOLESTEROL BLOOD LEVEL; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; YOGA; ADULT; BLOOD; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; METABOLISM; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES; YOGA;

EID: 84992477589     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12548     Document Type: Article

References (46)

1. Ali S, Davies MJ, Brady EM, et al. Guidelines for managing diabetes in Ramadan. Diabet Med 2016. doi: 10.1111/dme.13080.
2. Yang L, Shao J, Bian Y, et al. Prevalence of type 2 diabetes mellitus among inland residents in China (2000–2014): a meta-analysis. J Diabetes Investig 2016; 7: 845–852.
3. Joseph JJ, Golden SH. Type 2 diabetes and cardiovascular disease: what next? Curr Opin Endocrinol Diabetes Obes 2014; 21: 109–120.
4. American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care 2014; 37(Suppl 1): S14–S80.
5. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 2010; 33: e147–e167.
6. Temelkova-Kurktschiev T, Stefanov T. Lifestyle and genetics in obesity and type 2 diabetes. Exp Clin Endocrinol Diabetes 2012; 120: 1–6.
7. Lin CC, Li CI, Liu CS, et al. Impact of lifestyle-related factors on all-cause and cause-specific mortality in patients with type 2 diabetes: the Taichung Diabetes Study. Diabetes Care 2012; 35: 105–112.
8. Liu XC, Pan L, Hu Q, et al. Effects of yoga training in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Thorac Dis 2014; 6: 795–802.
9. Raub JA. Psychophysiologic effects of Hatha Yoga on musculoskeletal and cardiopulmonary function: a literature review. J Altern Complement Med 2002; 8: 797–812.
10. Chandler K. The emerging field of yoga therapy. Hawaii Med J 2001; 60: 286–287.
11. Singh S, Kyizom T, Singh KP, et al. Influence of pranayamas and yoga-asanas on serum insulin, blood glucose and lipid profile in type 2 diabetes. Indian J Clin Biochem 2008; 23: 365–368.
12. Kyizom T, Singh S, Singh KP, et al. Effect of pranayama & yoga-asana on cognitive brain functions in type 2 diabetes-P3 event related evoked potential (ERP). Indian J Med Res 2010; 131: 636–640.
13. Popli U, Subbe CP, Sunil K. Research letter-the role of yoga as a lifestyle modification in treatment of diabetes mellitus: results of a pilot study. Altern Ther Health Med 2014; 20: 24–26.
14. Jyotsna VP, Dhawan A, Sreenivas V, et al. Completion report: Effect of Comprehensive Yogic Breathing program on type 2 diabetes: A randomized control trial. Indian J Endocrinol Metab 2014; 18: 582–584.
15. Skoro-Kondza L, Tai SS, Gadelrab R, et al. Community based yoga classes for type 2 diabetes: an exploratory randomised controlled trial. BMC Health Serv Res 2009; 9: 33.
16. Shantakumari N, Sequeira S, El deeb R. Effects of a yoga intervention on lipid profiles of diabetes patients with dyslipidemia. Indian Heart J 2013; 65: 127–131.
17. Gordon LA, Morrison EY, McGrowder DA, et al. Effect of exercise therapy on lipid profile and oxidative stress indicators in patients with type 2 diabetes. BMC Complement Altern Med 2008; 8: 21.
18. Gordon L, Morrison EY, McGrowder DA, et al. Changes in clinical and metabolic parameters after exercise therapy in patents with type 2 diabetes. Arch Med Sci 2008; 4: 427–437.
19. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
20. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12.
22. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982–989.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
24. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
25. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
26. Habibi N, Farsani Z, Yazdani B, et al. The influence of yoga on risk profiles programs in women with diabetes type II. Adv Environ Biol 2013; 7: 550–555.
27. Monro R, Power J, Coumar A, et al. Yoga therapy for NIDDM: a controlled trial. Complement Med Res 1992; 6: 66–68.
28. Nagarathna R, Usharani MR, Rao AR, et al. Efficacy of yoga based life style modification program on medication score and lipid profile in type 2 diabetes-a randomized control study. Int J Diabetes Dev Ctries 2012; 32: 122–130.
29. Vaishali K, Kumar KV, Adhikari P, et al. Effects of yoga-based program on glycosylated hemoglobin level serum lipid profile in community dwelling elderly subjects with chronic type 2 diabetes mellitus–a randomized controlled trial. Phys Occup Ther in Geriatr 2012; 30: 22–30.
30. Shantakumari N, Sequeira S, Eldeeb R. Effect of a yoga intervention on hypertensive diabetic patients. J Adv Intern Med 2012; 1: 60–63.
31. Subramaniyan TG, Subramaniyan N, Chidambaram M. Brisk walking and yoga as adjuvant therapy in management of type 2 diabetes mellitus. Int J Stud Res 2012; 2: 43–46.
32. Pardasany A, Shenoy S, Sandhu JS. Comparing the efficacy of tai chi chuan and hatha yoga in type 2 diabetes mellitus patients on parameters of blood glucose control and lipid metabolism. Indian J Physiother Occup Ther 2010; 4: 11–16.
33. Innes KE, Vincent HK. The influence of yoga-based programs on risk profiles in adults with type 2 diabetes mellitus: a systematic review. Evid Based Complement Alternat Med 2007; 4: 469–486.
34. Innes KE, Selfe TK. Yoga for Adults with Type 2 Diabetes: A Systematic Review of Controlled Trials. J Diabetes Res 2016; 2016: 6979370.
35. de GR Hansen E, Innes KE. The benefits of yoga for adults with type 2 diabetes: a review of the evidence and call for a collaborative, integrated research initiative. Int J Yoga Therap 2013; 23: 71–83.
36. Aljasir B, Bryson M, Al-Shehri B. Yoga Practice for the Management of Type II Diabetes Mellitus in Adults: A systematic review. Evid Based Complement Alternat Med 2010; 7: 399–408.
37. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet 2002; 359: 696–700.
38. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast–the importance of defining different subsets of patients with COPD. Respir Res 2011; 12: 18.
39. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563–571.
40. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154–161.
41. Lee SD, Hui DS, Mahayiddin AA, et al. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology 2011; 16: 1249–1257.
42. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–694.
43. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695–703.
44. O'Donnell DE, Bredenbroker D, Brose M, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J 2012; 39: 1104–1112.
45. Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 2002; 18: 355–365.
46. Manninen P, Riihimaki H, Heliovaara M, et al. Physical exercise and risk of severe knee osteoarthritis requiring arthroplasty. Rheumatology (Oxford) 2001; 40: 432–437.